Skip to main content
Top
Published in: BMC Cancer 1/2002

Open Access 01-12-2002 | Research article

Expression of p53, inducible nitric oxide synthase and vascular endothelial growth factor in gastric precancerous and cancerous lesions: correlation with clinical features

Authors: Chang Wei Feng, Li Dong Wang, Lian Hua Jiao, Bin Liu, Shu Zheng, Xin Ji Xie

Published in: BMC Cancer | Issue 1/2002

Login to get access

Abstract

Background

The growth and metastasis of tumors depend on the development of an adequate blood supply via angiogenesis. Recent studies indicate that the inducible nitric oxide synthase (iNOS), vascular endothelial growth factor (VEGF) and the tumor suppressor p53 are fundamental play-markers of the angiogenic process. Overexpression of iNOS and VEGF has been shown to induce angiogenesis in tumors. P53 suppresses angiogenesis by down-regulating VEGF and iNOS. The correlation of expression of p53, VEGF and iNOS and clinical features in gastric carcinogenesis, however, has not been well characterized.

Methods

The expression of p53, iNOS and VEGF in gastric precancerous and cancerous lesions and its relation with the clinical features was determined with immunohistochemistry (avidin-biotin-peroxidase complex method) on 55 randomly selected GC patients and 60 symptom-free subjects from the mass survey in the high-incidence area for GC in Henan, northern China.

Results

The positive immunostainig rates for p53, iNOS and VEGF in gastric carcinomas were 51%, 44% and 51%, respectively, and correlated well with TNM stages, but did not show significant difference among the groups with different degrees of gastric wall invasion depth by GC. A positive immunostaining reaction for the iNOS protein was significantly correlated with lymph node metastasis (p = 0.019; Spearman correlation coefficient). P53 protein accumulation was higher in the poorly-differentiated gastric carcinoma than in well-differentiated one. In gastric biopsies, no positive immunosatining was observed for p53, iNOS and VEGF in the histologically normal tissue and chronic superficial gastritis (CSG). However, p53, iNOS and VEGF positive immunostaining was observed in the tissues with different severities of lesions of chronic atrophic gastritis (CAG), intestinal metaplasia (IM) and dysplasia (DYS), and the positive rates increased with the lesion progression from CAG to IM to DYS. A high coincidental positive and negative immunostaining rate for p53, iNOS and VEGF was observed both in biopsy samples with CAG, IM and DYS from the symptom-free subjects and in gastric cancer tissue from the GC patients.

Conclusions

The present results indicated that p53 protein accumulation and increased expression of iNOS and VEGF might be responsible for gastric carcinogenesis and tumor aggressiveness of gastric cancer.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ambs S, Bennet WP, Marriam WG, Ogunfusika MO, Oser SM, Khan MA, et al: Vascular endothelial growth factor and nitric oxide synthase expression in human lung cancer and the relation to p53. Br J Cancer. 1994, 59: 514-519. Ambs S, Bennet WP, Marriam WG, Ogunfusika MO, Oser SM, Khan MA, et al: Vascular endothelial growth factor and nitric oxide synthase expression in human lung cancer and the relation to p53. Br J Cancer. 1994, 59: 514-519.
2.
go back to reference Ambs S, Marriam WG, Bennet WP, Felley-bosco E, Ogunfusika MO, Oser SM, et al: Frequent nitric oxide synthase-2 expression in human colon adenomas: implication for tumor angiogenesis and colon cancer progression. Cancer Res. 1998, 58: 334-341.PubMed Ambs S, Marriam WG, Bennet WP, Felley-bosco E, Ogunfusika MO, Oser SM, et al: Frequent nitric oxide synthase-2 expression in human colon adenomas: implication for tumor angiogenesis and colon cancer progression. Cancer Res. 1998, 58: 334-341.PubMed
3.
go back to reference Ambs S, Bennet WP, Marriam WG, Ogunfusika MO, Oser SM, Anita M, et al: Relationship between p53 mutations and inducible nitric oxide synthase expression in human colorectal cancer. JNCI. 1999, 91: 86-88. 10.1093/jnci/91.1.86.CrossRefPubMed Ambs S, Bennet WP, Marriam WG, Ogunfusika MO, Oser SM, Anita M, et al: Relationship between p53 mutations and inducible nitric oxide synthase expression in human colorectal cancer. JNCI. 1999, 91: 86-88. 10.1093/jnci/91.1.86.CrossRefPubMed
4.
go back to reference Chiarugi V, Magnelli L, Gallo O: Cox-2, iNOS and p53 as play-markers of tumor angiogenesis (review). Int J Mol Med. 1998, 2: 715-719.PubMed Chiarugi V, Magnelli L, Gallo O: Cox-2, iNOS and p53 as play-markers of tumor angiogenesis (review). Int J Mol Med. 1998, 2: 715-719.PubMed
5.
go back to reference Correa P: Human gastric carcinogenesis. A multistep and multifactorial process–first American Cancer Society award lecture on cancer epidemiology and prevention. Cancer Res. 1992, 52: 6735-6740.PubMed Correa P: Human gastric carcinogenesis. A multistep and multifactorial process–first American Cancer Society award lecture on cancer epidemiology and prevention. Cancer Res. 1992, 52: 6735-6740.PubMed
6.
go back to reference Devavrata M, Leonidas T, Vikas PS: Wild-type p53 and v-src exert opposing influence on human vascular endothelial growth factor gene expression. Cancer Res. 1995, 55: 6161-6167. Devavrata M, Leonidas T, Vikas PS: Wild-type p53 and v-src exert opposing influence on human vascular endothelial growth factor gene expression. Cancer Res. 1995, 55: 6161-6167.
7.
go back to reference Forrester K, Ambs S, Lupold SE, Kapust RB, Spillare EA, Weinberg WC, et al: Nitric oxide induced p53 accumulation and regulation of inducible nitric oxide synthase (iNOS) expression by wild-p53. Natl Acad Sci USA. 1996, 93: 2442-2447. 10.1073/pnas.93.6.2442.CrossRef Forrester K, Ambs S, Lupold SE, Kapust RB, Spillare EA, Weinberg WC, et al: Nitric oxide induced p53 accumulation and regulation of inducible nitric oxide synthase (iNOS) expression by wild-p53. Natl Acad Sci USA. 1996, 93: 2442-2447. 10.1073/pnas.93.6.2442.CrossRef
8.
go back to reference Jekins DC, Charles LC, Thomsen LL, Moss DW, Holmes LS, Bayles SA, et al: Roles of nitric oxide in tumor growth. Natl Acad Sci USA. 1995, 92: 4393-4396. Jekins DC, Charles LC, Thomsen LL, Moss DW, Holmes LS, Bayles SA, et al: Roles of nitric oxide in tumor growth. Natl Acad Sci USA. 1995, 92: 4393-4396.
9.
go back to reference Nomura A: Stomach cancer. In: Cancer epidemiology and prevention. Edited by: Schottenfeld D and Fraumeni JF, eds. 1996, New York, Oxford University Press, pp707-720. Second Nomura A: Stomach cancer. In: Cancer epidemiology and prevention. Edited by: Schottenfeld D and Fraumeni JF, eds. 1996, New York, Oxford University Press, pp707-720. Second
10.
go back to reference Parkin DM, Muir C, Whelan SL, Gao YT, Ferlay J, Powell J, eds: Cancer incidence in five continents. In: Vol. VI Lyon, IARC Scientific Publications. 1992, 120: Parkin DM, Muir C, Whelan SL, Gao YT, Ferlay J, Powell J, eds: Cancer incidence in five continents. In: Vol. VI Lyon, IARC Scientific Publications. 1992, 120:
11.
go back to reference Wang LD, Shi ST, Zhou Q, Goldstin S, Hong JY, Shao P, et al: Changes in p53 and cyclin D1 protein levels and cell proliferation in different stages of human esophageal and gastric-cardia carcinogenesis. Int J Cancer. 1994, 59: 514-519.CrossRefPubMed Wang LD, Shi ST, Zhou Q, Goldstin S, Hong JY, Shao P, et al: Changes in p53 and cyclin D1 protein levels and cell proliferation in different stages of human esophageal and gastric-cardia carcinogenesis. Int J Cancer. 1994, 59: 514-519.CrossRefPubMed
12.
go back to reference World Health Organization: 1994. World Health Statistics Annual. Geneva: world Health Organization. 1994, pp396-407. World Health Organization: 1994. World Health Statistics Annual. Geneva: world Health Organization. 1994, pp396-407.
13.
go back to reference You WC, Blot WJ, Li JY, Chang YS, Jin ML, Kneller R, et al: Precancerous gastric lesions in a population at high risk of stomach cancer. Cancer Res. 1993, 53: 1317-1321.PubMed You WC, Blot WJ, Li JY, Chang YS, Jin ML, Kneller R, et al: Precancerous gastric lesions in a population at high risk of stomach cancer. Cancer Res. 1993, 53: 1317-1321.PubMed
14.
go back to reference Zhang LL, Yu D, Xiong SB, Lang A, Ellis LM, Pollock RE: Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression. Cancer Res. 2000, 60: 3661-3665. Zhang LL, Yu D, Xiong SB, Lang A, Ellis LM, Pollock RE: Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression. Cancer Res. 2000, 60: 3661-3665.
15.
go back to reference Maehara Y, Kabashima A, Koga T, Tokunaga E, Takeuchi H, Kakeji Y, Sugimachi K, et al: Vascular invasion and potential for tumor angiogenesis and metastasis in gastric carcinoma. Surgery. 2000, 128: 408-416. 10.1067/msy.2000.107265.CrossRefPubMed Maehara Y, Kabashima A, Koga T, Tokunaga E, Takeuchi H, Kakeji Y, Sugimachi K, et al: Vascular invasion and potential for tumor angiogenesis and metastasis in gastric carcinoma. Surgery. 2000, 128: 408-416. 10.1067/msy.2000.107265.CrossRefPubMed
16.
go back to reference Sakatani T, Okamoto E, Tsujitani S, Ikeguchi M, Kaibara N, Ito H, et al: Expression of thymidine phosphorylase (dThdPase) and vascular endothelial growth factor on angiogenesis in intestinal-type gastric carcinoma. Oncol Rep. 2000, 7: 831-836.PubMed Sakatani T, Okamoto E, Tsujitani S, Ikeguchi M, Kaibara N, Ito H, et al: Expression of thymidine phosphorylase (dThdPase) and vascular endothelial growth factor on angiogenesis in intestinal-type gastric carcinoma. Oncol Rep. 2000, 7: 831-836.PubMed
17.
go back to reference Ikeguchi M, Oka S, Saito H, Kondo A, Tsujitani S, Maeta M, Kaibara N, et al: Nuclear accumulation of p53 protein in gastric cancer strongly correlated with enlargement of nuclear area of cancer cells. Oncol Rep. 2000, 7: 579-584.PubMed Ikeguchi M, Oka S, Saito H, Kondo A, Tsujitani S, Maeta M, Kaibara N, et al: Nuclear accumulation of p53 protein in gastric cancer strongly correlated with enlargement of nuclear area of cancer cells. Oncol Rep. 2000, 7: 579-584.PubMed
18.
go back to reference Saito H, Tsujitani S, Ikeguchi M, Maeta M, Kaibara N, et al: Neoangiogenesis and relationship to nuclear p53 accumulation and vascular endothelial growth factor expression in advanced gastric carcinoma. Oncology. 1999, 57: 164-172. 10.1159/000012025.CrossRefPubMed Saito H, Tsujitani S, Ikeguchi M, Maeta M, Kaibara N, et al: Neoangiogenesis and relationship to nuclear p53 accumulation and vascular endothelial growth factor expression in advanced gastric carcinoma. Oncology. 1999, 57: 164-172. 10.1159/000012025.CrossRefPubMed
19.
go back to reference Maeda K, Kang SM, Onoda N, Ogawa M, Sawada T, Nakata B, Kato Y, Chung YS, Sowa M, et al: Expression of p53 and vascular endothelial growth factor associated with tumor angiogenesis and prognosis in gastric cancer. Oncology. 1998, 55: 594-599. 10.1159/000011918.CrossRefPubMed Maeda K, Kang SM, Onoda N, Ogawa M, Sawada T, Nakata B, Kato Y, Chung YS, Sowa M, et al: Expression of p53 and vascular endothelial growth factor associated with tumor angiogenesis and prognosis in gastric cancer. Oncology. 1998, 55: 594-599. 10.1159/000011918.CrossRefPubMed
20.
go back to reference Rajnakova A, Moochhala S, Goh PM, Ngoi S, et al: Expression of nitric oxide synthase, cyclooxygenase, and p53 in different stages of human gastric cancer. Cancer Lett. 2001, 172: 177-185. 10.1016/S0304-3835(01)00645-0.CrossRefPubMed Rajnakova A, Moochhala S, Goh PM, Ngoi S, et al: Expression of nitric oxide synthase, cyclooxygenase, and p53 in different stages of human gastric cancer. Cancer Lett. 2001, 172: 177-185. 10.1016/S0304-3835(01)00645-0.CrossRefPubMed
Metadata
Title
Expression of p53, inducible nitric oxide synthase and vascular endothelial growth factor in gastric precancerous and cancerous lesions: correlation with clinical features
Authors
Chang Wei Feng
Li Dong Wang
Lian Hua Jiao
Bin Liu
Shu Zheng
Xin Ji Xie
Publication date
01-12-2002
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2002
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-2-8

Other articles of this Issue 1/2002

BMC Cancer 1/2002 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine